Use of PCR testing in chronic myeloid leukemia.
Authors: Jabbour EJ PMID: 27058845 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging gene mutation targets in lung cancer.
Authors: Johnson BE PMID: 27058846 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The current and future applications of immunopharmacogenomics.
Authors: Nakamura Y PMID: 27058847 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of genetic alterations in the development of liver cancer drugs.
Authors: Abou-Alfa GK PMID: 27058848 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Molecular approaches to tumor inhibition in melanoma.
Authors: Davies MA PMID: 27058849 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.
In this report, we discuss emerging new therapies in relapsed and refractory PTCL and try to place these new findings in the evolving biological understanding of the disease. PMID: 27058850 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in immunotherapy for non-small cell lung cancer.
This article will review the recent progress made in immunotherapy for lung cancer with data from trials evaluating programmed death receptor 1 and cytotoxic T-lymphocyte-associated protein 4 monoclonal antibodies in addition to cancer vaccines. The review will focus on studies that have been published and the latest randomized trials exploring immune therapy in lung cancer. These results form the framework for a new direction in the treatment of lung cancer toward immunotherapy. PMID: 27058851 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Programmed death 1 immune checkpoint inhibitors.
Authors: Trivedi MS, Hoffner B, Winkelmann JL, Abbott ME, Hamid O, Carvajal RD Abstract Programmed death 1 (PD-1) is an immune checkpoint that provides inhibitory signals to the immune system in order to modulate the activity of T cells in peripheral tissues and maintain self-tolerance in the setting of infection and inflammation. In cancer, the immune checkpoints are exploited so that the tumor cells are able to evade the immune system. Immune checkpoint inhibitors are a type of cancer immunotherapy that targets pathways such as PD-1 in order to reinvigorate and enhance the immune response against tumor cells. The...
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27058853 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Authors: PMID: 27007002 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT.
Authors: PMID: 27007003 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
Authors: PMID: 27007004 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin.
Authors: PMID: 27007005 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
Authors: PMID: 27007006 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918). Clin Adv Hematol Oncol. 2016 Feb;14 Suppl 1(2):15-16 Authors: PMID: 27007007 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.
Authors: PMID: 27007008 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Lymphoma From the 2015 ASH Meeting: Commentary.
Authors: Chen RW PMID: 27007009 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962).
Authors: PMID: 27007010 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Rare Tumors of the Upper GI Tract: Neuroendocrine Tumors.
Authors: PMID: 27007139 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New Options for Neuroendocrine Tumors: Results of Recent Trials.
Authors: PMID: 27007140 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
Authors: PMID: 27007141 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate.
Authors: PMID: 27007142 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Peptide Receptor Radiation Therapy for Neuroendocrine Tumors.
Authors: PMID: 27007143 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment Patterns and Clinical Outcomes of Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs).
Authors: PMID: 27007144 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in GEP-NETs From the 2016 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Commentary.
Authors: Phan AT PMID: 27007145 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent Clinical Trials in Relapsed/Refractory Metastatic Colorectal Cancer.
Authors: Marshall JL PMID: 27007238 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimal Use of Regorafenib: Dosing Strategies and Patient Selection.
Authors: Grothey A PMID: 27007239 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of Metastatic Colorectal Cancer in the Community-Based Setting.
Authors: Seery TE, Tran P PMID: 27007240 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current Options for Third-Line Treatment of Metastatic Colorectal Cancer: Discussion.
Discussion. Clin Adv Hematol Oncol. 2016 Mar;14 Suppl 3(3):13-15 Authors: Grothey A, Marshall JL, Seery TE PMID: 27007241 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: Introduction.
Authors: Wang ES PMID: 27007406 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A Man With Pre-B-Cell, CD20-Negative ALL.
Authors: Jabbour EJ PMID: 27007407 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A Woman With CD19-Positive, B-Cell ALL.
Authors: Douer D PMID: 27007408 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A Man With CD10-Positive, CD34-Positive B-Cell ALL.
Authors: Wang ES PMID: 27007409 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 24, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Tumor Treating Fields and Other Technological Advances in the Treatment of Cancer.
Authors: Toms SA PMID: 26862770 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Clinical Use of Tumor Treating Fields and Other New Technologies in Cancer.
Authors: Wong ET PMID: 26862771 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Future Directions in the Use of Tumor Treating Fields and Other New Technologies in Glioblastomas and Other Cancers.
Authors: Ahluwalia MS PMID: 26862772 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Clinical Use of Tumor Treating Fields: Discussion.
Discussion. Clin Adv Hematol Oncol. 2015 Nov;13(11 Suppl 11):16-7 Authors: Wong ET, Toms SA, Ahluwalia MS PMID: 26862773 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Preliminary Efficacy and Safety of Brentuximab Vedotin and AVD Chemotherapy Followed by Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma.
Authors: PMID: 26862870 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Response-Adapted Therapy Based on Interim FDG-PET Scans in Advanced Hodgkin Lymphoma: First Analysis of the Safety of Deescalation and Efficacy of Escalation in the International RATHL Study (CRUK/07/033).
Authors: PMID: 26862871 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Sequential Brentuximab Vedotin and AVD for Older Hodgkin Lymphoma Patients: Initial Results From a Phase 2 Multicenter Study.
Authors: PMID: 26862872 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Addition of Thiotepa and Rituximab to Antimetabolites Significantly Improves Outcome in Primary CNS Lymphoma: First Randomization of the IELSG32 Trial.
Authors: PMID: 26862873 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Analysis of Primary-Refractory Hodgkin Lymphoma Pts in a Randomized, Placebo-Controlled Study of Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplant.
Authors: PMID: 26862874 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Early FDG-PET Adapted Treatment Improves the Outcome of Early FDG-PET-Positive Patients With Stages I/II Hodgkin Lymphoma (HL): Final Results of the Randomized Intergroup EORTC/LYSA/FIL H10 Trial.
Authors: PMID: 26862875 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Brentuximab Vedotin Plus AVD for Non-Bulky Limited Stage Classical Hodgkin Lymphoma: A Phase 2 Trial.
Authors: PMID: 26862876 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Rituximab, Bendamustine and Cytarabine (RBAC500) as Induction Therapy in Elderly Patients With Mantle Cell Lymphoma: A Phase 2 Study From the Fondazione Italiana Linfomi.
Authors: PMID: 26862877 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Lymphoma From the 13th International Conference on Malignant Lymphoma: Commentary.
Authors: Moskowitz CH PMID: 26862878 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Guiding Principles in the Management of Chemotherapy-Induced Nausea and Vomiting.
Authors: Roeland E PMID: 26859507 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 11, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of Chemotherapy-Induced Nausea and Vomiting: A Review of Current Data.
Authors: Aapro MS PMID: 26859508 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 11, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Best Use of Guidelines for the Management of Chemotherapy-Induced Nausea and Vomiting.
Authors: Schwartzberg LS PMID: 26859509 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 11, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Q&a.
Q&A. Clin Adv Hematol Oncol. 2015 Oct;13 Suppl 10(10):12-13 Authors: Roeland E, Schwartzberg LS, Aapro MS PMID: 26859510 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 11, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research